Latest Nasdaq News

Aurora Energy Metals progresses the Aurora Uranium Project with a major drill program imminent under Eagle Nuclear Energy, while broadening its Western Australian footprint with new exploration licences at Mukinbudin.

Battery Age Minerals has identified multiple priority exploration targets at its Apex Project in Utah, submitted new drilling permits for Austria’s Bleiberg site, finalised a commercial germanium technology licence, and gained entry to a US defense consortium, underpinning its integrated germanium strategy.

Clinuvel Pharmaceuticals targets year-end for topline results from its pivotal vitiligo trial of SCENESSE® combined with narrowband UVB, aiming to expand the drug's use beyond its current rare disease indication.

Elevra Lithium’s North American Lithium operation hit a new monthly spodumene concentrate production record in May 2026 while closing a US$298 million financing package to fund expansion and project development.

European Lithium (ASX: EUR) has obtained a crucial ASX waiver allowing it to cancel unlisted options and performance rights without shareholder approval, smoothing the path for its acquisition by NASDAQ-listed Critical Metals Corp (NASDAQ: CRML).

Reach Resources has locked in a fully funded mining and milling agreement with Andel Resources at Murchison South, alongside a 30% increase in its Blue Heaven gold resource to 80,000 ounces at higher grade.

CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.

Energy World Corporation is progressing on its US$350 million turbine sale to Hallador Energy with equipment packing underway and funds partially received. The company is also refining its Pagbilao LNG terminal strategy while facing challenges in divesting Australian assets.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Almonty Industries will delist from the Toronto Stock Exchange by July 31, 2026, focusing its trading exclusively on Nasdaq to streamline costs and align with where most activity occurs.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.

Marlin Global's portfolio delivered a 2.0% gross return in Q2 2026, driven by rebounds in ICON and semiconductor holdings, but lagged a strong US market rally led by AI and chip stocks.